Annals of Family Medicine
NOVEMBER 20, 2024
Results: The proportion of patients with a premium billed for diabetes or hypertension was highest in small urban areas, but lower amongst patients with SMI across all three geographic settings, with particularly low values in metro.
Today's Hospitalist
JUNE 7, 2025
THE BLOCKBUSTER GLP-1 receptor agonists are a transformative class of medications increasingly tied to better outcomes across a variety of conditions and organ systems, not just in patients with obesity and type 2 diabetes. Published in May 2024, the FLOW trial , for instance, looked at patients with diabetes and advanced kidney disease.
GeriPal
JANUARY 16, 2025
So you mentioned the burden of chronic multimorbidity and sort of flogging through the diabetes and the hypertension. It’s been revised in 2023. But I think the most important thing is just to, to recognize, to ask these types of questions. I think it’s.
Expert insights. Personalized for you.
130 
Let's personalize your content